136 related articles for article (PubMed ID: 34348171)
1. Pancreatic Stereotactic Body Radiation Therapy With or Without Hypofractionated Elective Nodal Irradiation.
Miller JA; Toesca DAS; Baclay JRM; Vitzthum LK; Dubrowski P; Pollom EL; Chang DT
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):131-142. PubMed ID: 34348171
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer.
Libbey N; Gallagher L; Cantalino J; Weinberg BA; Noel MS; He AR; Radkani P; Marshall JL; Weiner LM; Jackson PG; Fishbein TM; Winslow ER; Haddad N; Rashid A; Unger KR
J Gastrointest Cancer; 2024 Jun; 55(2):852-861. PubMed ID: 38347342
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.
Witt JS; Kuczmarska-Haas A; Lubner M; Reeder SB; Cho SY; Minter R; Weber S; Ronnekleiv-Kelly S; Abbott D; LoConte N; Mulkerin DL; Lubner SJ; Uboha NV; Deming D; Ritter MA; Mohindra P; Bassetti MF
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):458-463. PubMed ID: 32942002
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
6. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.
Wild AT; Hiniker SM; Chang DT; Tran PT; Khashab MA; Limaye MR; Laheru DA; Le DT; Kumar R; Pai JS; Hargens B; Sharabi AB; Shin EJ; Zheng L; Pawlik TM; Wolfgang CL; Koong AC; Herman JM
J Gastrointest Oncol; 2013 Dec; 4(4):343-51. PubMed ID: 24294505
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation.
Komatsu T; Kunieda E; Kitahara T; Akiba T; Nagao R; Fukuzawa T
J Radiat Res; 2016 Jan; 57(1):75-83. PubMed ID: 26566656
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study.
Topkan E; Ozdemir Y; Guler OC; Kucuk A; Besen AA; Mertsoylu H; Sezen D; Akdemir EY; Sezer A; Bolukbasi Y; Pehlivan B; Selek U
J Oncol; 2020; 2020():7083149. PubMed ID: 32952557
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
11. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
[TBL] [Abstract][Full Text] [Related]
12. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection.
Ji X; Zhou B; Ding W; Wang J; Jiang W; Li Y; Hu J; Sun X
Front Oncol; 2022; 12():925043. PubMed ID: 35936670
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
15. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
Courtney PT; Paravati AJ; Atwood TF; Raja N; Zimmerman CT; Fanta PT; Lowy AM; Simpson DR; Xu R; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1003-1012. PubMed ID: 33571625
[TBL] [Abstract][Full Text] [Related]
17. Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials.
Glicksman RM; Liu SK; Cheung P; Vesprini D; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Musunuru HB; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Oct; 163():159-164. PubMed ID: 34487764
[TBL] [Abstract][Full Text] [Related]
18. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
19. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.
McDonald AM; Baker CB; Popple RA; Shekar K; Yang ES; Jacob R; Cardan R; Kim RY; Fiveash JB
Radiat Oncol; 2014 Jun; 9():129. PubMed ID: 24893842
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.
Kinj R; Doyen J; Hannoun-Lévi JM; Naghavi AO; Chand ME; Baudin G; Ferrero JM; François E; Evesque L; Borchiellini D; Benezery K; Bondiau PY
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e15-e21. PubMed ID: 32641243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
